Glesatinib is a TKI that targets tumors with MET and AXL alterations.
Glesatinib exhibits anti-tumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance.
Nonclinical models have shown glesatinib to be effective in MET exon 14 skipping mutations. It is currently being evaluated in phase II trials in NSCLC patients with MET alterations.
Glesatinib (MGCD265; 15 mg/kg/day; orally; 40 weeks) causes a significant decrease in tumor size[1].
| Animal Model: | 46-week old female balb/c athymic (nu/nu) mice with HCC827 NSCLC tumor xenografts[1] |
| Dosage: | 15 mg/kg |
| Administration: |
Orally; daily; 40 weeks |
| Result: | Caused a significant decrease in tumor size.
|
